Invited Discussant: Perioperative EV + Pembrolizumab in #MIBC – KEYNOTE-905 and KEYNOTE-B15 ctDNA Analyses. Presented by @MTeoMD @MSKCancerCenter. #ESMO26 written coverage by @chav

UroToday.com· @urotoday · X·2026-10-24 03:45· 2 days agoScore70

Body · original

Invited Discussant: Perioperative EV + Pembrolizumab in #MIBC – KEYNOTE-905 and KEYNOTE-B15 ctDNA Analyses. Presented by @MTeoMD @MSKCancerCenter. #ESMO26 written coverage by @chavarriagaj @PSH_Urology > https://bit.ly/3TYzso1 #BladderCancer #Immunotherapy @myESMO

425 views · 4 likes · 5 reposts · 0 replies

Conference abstracts

4733Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905

https://esmocongress.esmo.org

NCT03924895NCT03924895matched by - **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

- **标题 / Title：** Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

https://esmocongress.esmo.org

Source: UroToday.com · x.com